Preclinical (mouse + in vitro) · PMID 41921651
NAD+ supplementation attenuates hypoxia-exacerbated oral mucosal inflammation via lactate metabolic reprogramming — VialBase Research
Acute hypoxia activates Wnt/beta-catenin --> HIF-1alpha --> LDHA --> accelerated lactate synthesis
Last updated · 2026 · Various · J Dent
Key findings
- Acute hypoxia activates Wnt/beta-catenin --> HIF-1alpha --> LDHA --> accelerated lactate synthesis
- Lactate amplifies NF-kB activation and inflammatory cytokine secretion
- NAD+ supplementation significantly attenuated inflammatory responses in vitro and in vivo
- Lactate metabolic reprogramming is central regulator of hypoxia-exacerbated inflammation
- Clinical relevance for high altitude, sleep apnea patients
NAD+ Attenuates Hypoxia-Driven Inflammation via Lactate Pathway (PMID: 41921651)
Study Design
- Acute hypoxia-induced oral mucosal inflammation model (mice)
- In vitro oral mucosal fibroblasts
- Analyzed Wnt/beta-catenin —> HIF-1alpha —> LDHA signaling axis
- Tested galloflavin (lactate inhibitor) and NAD+ supplementation
Key Results
- Hypoxia —> Wnt/beta-catenin activation —> HIF-1alpha + LDHA upregulation
- Accelerated lactate synthesis in fibroblasts
- Lactate = key mediator amplifying NF-kB and inflammatory cytokines
- Both lactate inhibition AND NAD+ supplementation attenuated inflammation
- In vivo: NAD+ alleviated oral mucosal damage
Mechanism Insight
NAD+ supplementation works here by countering the metabolic shift toward glycolysis/lactate production. By maintaining NAD+/NADH balance, cells can continue oxidative phosphorylation rather than defaulting to glycolysis, which produces the lactate that drives inflammation.
Clinical Significance
Relevant for patients experiencing hypoxia (high altitude, sleep apnea, COPD) who develop worsened mucosal inflammation. NAD+ supplementation as a novel intervention for hypoxic inflammatory diseases.
See Also
- Parent compound: NAD+